Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases
Pablo García‐Pavía(Universidad Francisco de Vitoria), Aleš Linhart(Charles University), Claudio Rapezzi(Boston University), Urs Eriksson(University of Zurich), Ingrid Kindermann(Baker Heart and Diabetes Institute), Michael Arad(Tel Aviv University), Sabine Pankuweit(Universitätsklinikum Gießen und Marburg), Marianna Fontana(Johnson & Johnson (United States)), Massimo Imazio, Alida L.P. Caforio(University of Padua), Julian D. Gillmore(Alnylam Pharmaceuticals (United States)), Matthew J. Maurer(Boston University), Stéphane Heymans(Maastricht University), Yehuda Adler, Arnt V. Kristen(Université Paris-Sud), Thibaud Damy(Amyloidosis Foundation), Martha Grogan(Boston University), Esther González-López(Children's Cancer and Leukaemia Group), Giampaolo Merlini(University of Pavia), Ivana Burazor(University of Belgrade), Angelos G. Rigopoulos(Luther University), Antonis Pantazis(Harefield Hospital), Antonio Brucato(Azienda Ospedaliera Fatebenefratelli e Oftalmico)
Cited by 1,142
Related Papers
Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases
|European Heart Journal|2013|3.4k
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
2015 ESC Guidelines for the diagnosis and management of pericardial diseases
|European Heart Journal|2015|2.6k
2023 ESC Guidelines for the management of cardiomyopathies
|European Heart Journal|2023|2.3k